Bristol-Myers Squibb Ends Cancer Drug Deal with Pierre Fabre
"In Europe, Pierre Fabre Medicament intend to continue discussions with regulatory authorities and plan to file for the registration of vinflunine for bladder cancer in the first quarter of 2008," said P. Hurteloup, General Manager of Pierre Fabre Medicament Oncology Division. "We also are considering a range of further development options, including pursuing the product on a worldwide basis for the treatment of a number of cancers."
Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.
Pierre Fabre Medicament is a French private group dedicated to consumers and patients from health to beauty.
Source: Bristol-Myers Squibb Company; Pierre Fabre Medicament